|
Surgery benefits patients with renal disease, primary hyperparathyroidism - Healio |
|
|
|
In patients with coexisting primary hyperparathyroidism and renal disease, parathyroidectomy stopped the progression of renal function deterioration, according to recent findings in a retrospective cross-sectional study.
Francesco Tassone, MD, PhD,of Santa Croce and Carle Hospital in Cuneo, Italy, and colleagues evaluated the charts of 109 consecutive patients with primary hyperparathyroidism treated with parathyroidectomy between 1995 and 2012. The researchers extracted the following biochemistry data from the patient charts: BMI, systolic blood pressure, diastolic BP, creatinine, serum immunoreactive parathyroid hormone and 25-hydroxyvitamin D3 concentration. Participants also were tested with plain radiograph of the abdomen or ultrasound of the kidneys. The researchers used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation to evaluate estimated glomerular filtration rate.
The researchers found that, at diagnosis, the participants had a mean eGFR of 82.4 ± 19.3 mL/min/1.72 m2. Compared with those with an eGFR lower than 60 mL/min/1.73 m2, those with eGFR of 60 mL/min/1.73 m2 or more tended to be younger (P < .0003).
In the participants with the lower eGFR, the measure did not change after parathyroidectomy compared with a decrease in eGFR in those participants with baseline eGFR of 60 mL/min/1.73 m2or higher (P < .0002).
There was an inverse association between the difference in eGFR and postsurgery values and baseline serum creatinine (P = .0052), whereas the difference was positively correlated with baseline CKD-EPI eGFR values (P= .00062).
Multiple regression revealed that only systolic BP and baseline eGFR were independently predictive of eGFR changes.
“Our data show that surgical cure of [primary hyperparathyroidism] halts renal function worsening in patients with concomitant renal disease, thus supporting current guidelines that recommend surgery for [primary hyperparathyroidism] patients whose GFR is below 60 mL/min/1.73 m2,” the researchers wrote. “Moreover, our data also show that presurgical renal function is the most relevant predictor of renal function change after [parathyroidectomy].” – by Jennifer Byrne
Disclosure: The researchers report no relevant financial disclosures.
|
|
Prostatitis Found to Increase Prostate Cancer Risk - Renal and Urology News |
|
|
June 29, 2015
Researchers observe no association between prostate cancer and urethritis, orchitis, or epididymitis.
Men with a history of prostatitis are at elevated risk of prostate cancer (PCa), according to a new study presented at the Canadian Urological Association annual meeting in Ottawa.
In a study of 1,884 PCa patients and 1,965 controls, Katharina Boehm, MD, of Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, and colleagues demonstrated that a history of prostatitis was associated with a significant 83% increased risk of PCa being found at biopsy. The investigators observed no increased risk of PCa associated with urethritis, orchitis, or epididymitis.
Among individuals with prostatitis, those without a history of benign prostatic hyperplasia (BPH) had a nearly 3-fold increased risk of PCa, whereas those with a history of BPH had a significant 30% decreased risk.
In their study abstract, the researchers concluded that their findings “should be used in clinical risk stratification of individuals in whom the risk of PCa is pertinent.”
|
|
|
Rockwell Medical, Inc. (NASDAQ:RMTI) Brokerage Rating Update - Investor Newswire |
|
|
|
Rockwell Medical, Inc. (NASDAQ:RMTI) has been handed a rating of 2 on a consensus basis by Zacks Research. Using a simplified 1 to 5 scale where 5 represents a Strong Sell and 1 a Strong Buy, 4 analysts polled by Zacks had their ratings weighed into this average. In order to measure the direction of the analyst sentiment, the same analysts had a rating of 2 on the equity three months ago.
Sell-side analysts covering Rockwell Medical, Inc. (NASDAQ:RMTI) have a one year price average objective of $16.25 on the equity. The targets range from $4 to $26, according to the data from research firms surveyed by Zacks.
Earnings in Focus Analysts on the Street are anticipating Rockwell Medical, Inc. will report earnings per share of $-0.1 for the fiscal quarter ending on 2015-06-30. Estimates from 4 brokers were taken into consideration to arrive at this estimate. Looking ahead on a three to five year basis, Wall Street is expecting earnings of $25 per share on the stock. This is the best estimate according to Zacks for sales and earnings over that time span. Investors and analysts alike will be marking their calendars when Rockwell Medical, Inc. is expected to report earnings on 2015-07-30. The company will be trying to improve on the previous quarter’s numbers of $-0.07 for the quarter ending on 2015-03-31. The actual EPS was 30% away from what analysts had expected, or a $0.03 difference. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
|
|
NxStage Medical, Inc. (NASDAQ:NXTM) Analyst Rating Update - Investor Newswire |
|
|
|
Wall Street analysts polled by Zacks Research have given NxStage Medical, Inc. (NASDAQ:NXTM) a rating of 2 on a consensus basis. Using a simplified scale where 1 is a Strong Buy and 5 a Strong Sell, this is the average number of the 4 brokerages surveyed. The stock had a rating of 2 when analyst ratings were averaged three months ago.
The covering analysts have a one year price objective of $21 on NxStage Medical, Inc. (NASDAQ:NXTM). The most bullish brokerage firm sees the stock heading to $24 , while the most conservative estimate has an objective of $15.
Earnings Look Wall Street will be paying close attention when NxStage Medical, Inc. reports their next quarterly earnings report on 2015-08-06. Analysts polled by Zacks are expecting earnings per share of $-0.1 for the period ending 2015-06-30. This is the consensus number based on the 4 broker predictions taken into consideration. On a longer term basis, sell-side analysts who project long term growth are expecting earnings of $18.33. This is the three to five year estimate for both earnings and sales. Most recently NxStage Medical, Inc. reported actual earnings of $0 per share for the quarter ending on 2015-03-31. The actual reported number was $0.11 away from what analysts had expected, yielding a surprise factor of 100%. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
|
|